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Abstract
Aim: The diagnosis of hepatocellular carcinoma (HCC) in the early stage is crucial to the application of curative treatments
which are the only hope for increasing the life expectancy of patients. Recently, several large-scale studies have shed light
on this problem through analysis of gene expression profiles to identify markers correlated with HCC progression. However,
those marker sets shared few genes in common and were poorly validated using independent data. Therefore, we
developed a systems biology based classifier by combining the differential gene expression with topological features of
human protein interaction networks to enhance the ability of HCC diagnosis.
Methods and Results: In the Oncomine platform, genes differentially expressed in HCC tissues relative to their
corresponding normal tissues were filtered by a corrected Q value cut-off and Concept filters. The identified genes that are
common to different microarray datasets were chosen as the candidate markers. Then, their networks were analyzed by
GeneGO Meta-Core software and the hub genes were chosen. After that, an HCC diagnostic classifier was constructed by
Partial Least Squares modeling based on the microarray gene expression data of the hub genes. Validations of diagnostic
performance showed that this classifier had high predictive accuracy (85.88,92.71%) and area under ROC curve
(approximating 1.0), and that the network topological features integrated into this classifier contribute greatly to improving
the predictive performance. Furthermore, it has been demonstrated that this modeling strategy is not only applicable to
HCC, but also to other cancers.
Conclusion: Our analysis suggests that the systems biology-based classifier that combines the differential gene expression
and topological features of human protein interaction network may enhance the diagnostic performance of HCC classifier.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignant tumors with an increasing incidence worldwide. The
resistance of HCC to existing treatments and the lack of biomarkers
for early detection make it one of the most hard-to-treat cancers.
High-risk patients with HCC are closely followed up and increasing
numbers of small equivocal lesions, which are widely recognized as
dysplastic nodules or early-stage HCC, lack typical imaging and
histology of ordinary HCC and do not show elevated serum markers,
such as alpha-fetoprotein (AFP) and PIVKA-II [1–2]. Given the
importance of early-stage diagnosis to the application of curative
treatments which are the only hope for increasing the life expectancy
of patients with HCC, the development of effectivesystemswhichcan
predict the occurrence of this neoplasm is much needed.
Several attempts have been made to predict the occurrence and
prognosis of HCC based on single or multiple clinicopathologic
features such as the severity of the liver function, age, tumor size,
grade, microvascular invasion, portal vein thrombosis, and the
presence of microsatellite regions [3–4]. However, their clinical
applicability is worthy of further large-scale validations. Recent
studies on gene expression profiles could successfully predict the
occurrence, progression, or survival of cancers [5–6], but the lack
of consistency of these microarray-based predictors generated
from the heterogeneity of the patient cohorts and the difference in
microarray platforms remain one of the major obstacles to their
clinical use, making it necessary to identify a reliable and
consistent predictor that is robust enough to overcome the
variabilities induced by different platforms or different patient
cohorts.
There have been several approaches to this problem from
different perspectives. One approach performs a gene pathway-
based analysis, which identifies biological pathways by scoring the
coherency of expression changes among their member genes based
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incorporate previously accumulated biological knowledge in the
analysis and make a more biology-driven analysis of microarray
data, which can help identify interpretable discriminative
signatures that gains insight into tumor biology and potential
therapeutic targets. In addition, this method enables the
identification of moderately differentially expressed but function-
ally important genes, which are missed in gene expression
clustering. A second approach is a protein interaction network-
based method, which utilizes a recently available protein-protein
interaction network to identify sub-networks based on coherent
expression patterns of their genes [8]. A sub-network refers to a
smaller or more focused network within a large protein interaction
network [9]. Both methods efficiently utilize co-expression
information embedded within the microarray gene expression
data. However, the problem with both methods is that each gene
set or sub-network identified includes too many genes, which
greatly limits their clinical application.
Lu et al. [10] demonstrated that hubs of biological network have
significantly different biological functions compared with periph-
eral nodes based on Gene Ontology classification, and that
biological understanding of experimental asthma is enhanced by
combining information including levels of change in gene
expression plus topological criteria from the analysis of interaction
networks. We hypothesized that developing a systems biology-
based approach by combining differential gene expression and
topological characteristics of human protein interaction networks
could improve the diagnostic performance of HCC classifier.
Materials and Methods
The technical strategy of this study was shown in Figure 1.
Gene expression microarray analysis
The data mining strategy for selecting marker genes for our
classifier is based on a published methodology exploring the cancer
microarray platform, Oncomine [11] (16 SEP 2008 ONCOMINE
DATA RELEASE HIGHLIGHTS, https://www.oncomine.org),
which was chosen because it is a public cancer microarray platform
incorporating 392 independent microarray datasets, totaling more
than 28,880 microarray experiments and spanning 41 cancer types.
It unifies a large compendium of other published cancer microarray
data, including Gene Expression Omnibus (GEO) [12] and
Stanford Microarray Database (SMD) [13], and uniquely provides
differential expression analyses comparing most major types of
cancer with their respective normal tissues. For example, to identify
potentially important genes in a particular cancer, users can
perform a ‘‘cancer vs. normal’’ analysis for a given cancer type and
those genes that are differentially expressed in cancer relative to its
normal tissue can be retrieved as a list. Each differentially expressed
gene in the list can then be assessed by the Student t test to calculate
the P or Q values (false discovery rate) [14], mean expression values
(mean 1, mean 2), and the normalized Student t value. In addition,
Oncomine is integrated with the Concept filter, which allows users
to identify genes with certain biological processes or mutation types.
Public expression datasets. Hepatocellular carcinoma was
used in the ,profile search. function in the Oncomine database to
find the available microarray datasets related to the specific cancer
type. The analysis type ,cancer vs. non-tumor. was then applied to
filter those microarray datasets exploring cancer relative to its non-
tumor tissue. Three publicly available datasets of gene expression
profileswere chosen inthisstudy, including Chen_Liver_1[15](Non-
tumor Liver vs. Hepatocellular Carcinoma), Chen_Liver_2
[15] (Non-tumor Liver vs. Hepatocellular Carcinoma), and
Wurmbach_Liver [16] (Non-tumor Liver vs. Hepatocellular
Carcinoma). The detailed information about the datasets is
described in Raw Data S1, S2, S3, S4, S5 and Table S1.
Gene selection procedure. Concept filters in the Oncomine
database were used to identify known oncogenes differentially
expressed in HCC. Specifically, differentially expressed genes
associated with the following Concept filter terms were searched:
,CAN Genes., ,The Cancer Gene Census., ,Catalogue of
Somatic Mutations in Cancer (COSMIC)., ,Drug target-
experimental. and ,Drug target-FDA.. Next, a corrected
false discovery rate Q value threshold (Q#0.05) was used to filter
and retrieve those differentially expressed genes with a high
confidence. Then, the differentially expressed genes identified
throughout the three microarray gene expression datasets were
selected as candidate genes for further network analysis.
Network analysis
The network representationwasgenerated usingGeneGO Meta-
Core software (Encinitas, CA). The software interconnected all
candidate genes according to published literature-based annota-
tions. Only direct connections between the identified genes were
considered. Major hubs were defined as those with more than thirty
connections and ,50% of edges hidden within the network. The
hub genes were selected as the components of HCC classifier.
Systems biology-based HCC classifier construction
Datasets. To demonstrate this novel classifier, two publicly
available datasets of gene expression profiles were used in this
study, including Chen_Liver [15] (29 HCC samples and 17 non-
tumor liver samples) and Wurmbach_Liver [16] (35 HCC samples
and 27 non-tumor liver samples) datasets. These datasets were
randomly separated into the training and test datasets for 100
times. The detailed information about the datasets is described in
Raw Data S1, S2, S3, S4, S5.
Parial Least Squares classifier. Parial Least Squares (PLS),
which can extract effective information form a larger number of
predictors, was used to construct the systems biology-based HCC
classifier. To describe this method, some notations are required.
Let x be n|p matrix of n samples and p hub genes. Also, let y
denote the n|1 vector of response values, such as the indicator of
HCC or non-tumor liver tissues. The objective criterion for
constructing components in PLS is to sequentially maximize the
covariance between the response variable and a linear
combination of the predictors. The components are constructed
to maximize the objective criterion based on the sample
covariance between y and xc. Thus, we find the weight vector w
satisfying the following objective criterion,
w~argmaxcov2(xw,y) ð1Þ
Next, a training dataset was used to calculate weight coefficients of
different hub genes in PLS model. The hub genes in PLS model
are denoted as:
p~fpig, i~1,2,3,4,5,6,7,8 ð2Þ
The score of the PLS model for each sample is defined as:
Score~
X
LPi|WPi,i~1,2,3,4,5,6,7,8 ð3Þ
Where LPi refers to the expression level of hub gene pi in each
sample.
Systems Biology Modeling for HCC Diagnosis
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so as to calculate the threshold value T of score by selecting the
cutoff value on which the Area under Receiver Operating
Characteristic (ROC) Curve (AUC) was the biggest. Finally, the
PLS classifier decides: if ScorewT, the sample can be predicted as
HCC tissues.
Performance evaluation
The overall performance of HCC classifier was evaluated by
two distinct approaches: 5-fold cross-validation test and indepen-
dent dataset test. The overall predictive accuracy (ACC) and AUC
were used to measure the prediction performance of our method.
ROC Curve can show the efficacy of one test by presenting both
Figure 1. A schematic diagram of this novel systems biology-based gene expression classifier for HCC diagnosis. First, the genes
differentially expressed in HCC tissues relative to their corresponding non-tumor tissues were filtered by a corrected Q value cut-off and Concept
filters in the Oncomine platform. The identified genes that are common among different microarray datasets were chosen as the candidate genes.
Then, their networks were analyzed by GeneGO Meta-Core software and the hub genes were chosen. After that, HCC diagnostic classifier was
constructed by PLS modeling based on the microarray gene expression data of the hub genes. Finally, the diagnostic performance of this classifier
was evaluated by predictive accuracy and area under ROC curve.
doi:10.1371/journal.pone.0022426.g001
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and specificity can measure the ability of a test to identify true
positives and false ones in a dataset.
Sensitivity~
TP
TPzFN
ð4Þ
Specificity~
TN
TNzFP
ð5Þ
ACC~
P
TPzTN
N
ð6Þ
where TP, TN, FP, FN respectively refer to the number of true
positive, true negative, false positive and false negative result
components in a test, while N refers to the total number of
predicted samples.
The ROC curves are plotted and smoothed by SPSS software
with the sensitivity on the y axis and 1-Specificity on the x axis.
In the 5-fold cross-validation test, the dataset was randomly
divided into 5 sets, four of which were used to train the parameters
of the predictive algorithm. The predictive accuracy of the
algorithm was then evaluated by the remaining set, and this
procedure was repeated five times before sensitivity and specificity
against different parameters across five test datasets are calculated
for the ROC curve.
Validation of MAPK1 and NCOA2 hubs
Patients and tumor tissue specimens. The study was
approved by the Research Ethics Committee of Affiliated Huai’an
1
st People’s Hospital, Nanjing Medical University Huai’an,
Jiangsu, P.R.China. Written Informed Consent was obtained
from each of the patients. All specimens were handled and made
anonymous according to the ethical and legal standards.
Thirty matched HCC and paracarcinomatous liver tissue
(PCLT) specimens were obtained from 30 patients who underwent
hepatectomy at the Department of Hepatobiliary & Pancreatic
Surgery at this hospital between 2007 and 2009. These patients
included 22 males and 8 females with a median age of 52.4 years
(range, 30,76 years). No patients who had undergone previous
therapy or non-curative surgery were included. The clinicopath-
ologic variables, such as tumor size, etiological factors, underlying
disease, portal vein infiltration, Edmondson-Steiner grade, TNM
stage, AFP levels, lymphatic metastasis status, and differentiation
degree, were recorded and summarized in Table S9. All specimens
were fixed in 10% formalin, embedded in paraffin, and cut into
4 mm serial sections for immunohistochemical staining, in addition
to the usual hematoxylin-eosin staining.
Immunohistochemistry. For immunohistochemical stain-
ing, tissues were fixed in 10% buffered formalin and embedded in
paraffin. Commercially available rabbit anti-human polyclonal
antibody against MAPK1 (dilution 1:100; Catalog No.: 51068-1-
AP; ProteinTech Group, Inc., Chicago, IL, USA) and rabbit anti-
human polyclonal antibody against NCOA2 (dilution 1:1000;
Catalog No.: ab10508; Abcam (Hong Kong) Ltd., Hong Kong)
were used. Immunohistochemical staining was carried out on
sections using the avidin-biotin method and a commercially
available kit (Vectastain Elite ABC kit, Vector Laboratories,
Burlingame, CA). Briefly, sections (4 mm thick) were incubated
overnight at 4uC with the primary antibodies against MAPK1 and
NCOA2, respectively. After being washed in PBS, a biotin-marked
secondary antibody was applied for 10 min followed by a
peroxidase-marked streptavidin for an additional 10 min. The
reaction was visualized by using 3, 39-diaminobenzidine
tetrahydrochloride. The nuclei were counterstained with
hematoxylin. Negative controls were carried out by omitting the
primary antibodies while MAPK1 and NCOA2 overexpression
confirmed by Western blotting were used as positive controls,
respectively.
Immunoreactivity was assessed by two investigators who were
blinded to clinicopathologic data. Discrepancies were resolved by
simultaneous reexamination of the slides by both investigators
using a double-headed microscope. A semiquantitative scoring
system was used as previously reported [18]. The stain was graded
as 0 (negative), 1(weak), 2 (moderate), and 3 (strong). The final
score was the sum total of the product of the staining intensity and
corresponding tumor percentage. For example, if a tumor showed
50% moderate staining and 50% strong staining, the final score
would be (5062)+(5063)=250. A final score of at least 100 was
considered positive expression.
Statistical Analysis
A comparison of the prediction performance of HCC classifiers
with different hub/non-hub genes was made using Fisher’s exact
test for any 262 tables by using SPSS13.0 [19]. Differences were
considered to be statistically significant when the P value was less
than 0.05.
Results
Identification of candidate HCC markers for network
analysis
Data mining of three microarray datasets from the Oncomine
platform for genes differentially expressed in HCC tissues
compared with their expression in non-tumor liver tissues led to
the identification of a list of 6582 upregulated and 5101
downregulated gene expression profiles. Then, 1098 cancer-
related genes (including 469 upregulated and 629 downregulated
genes) were searched from this gene list by a combination of
controlled Concept filter terms. When the retrieved genes were
further filtered by the corrected false discovery rate Q (Q#0.05)
and intersection screening, 116 upregulated and 111 downregu-
lated genes were selected as candidate marker genes for further
network analysis (the detailed information of this gene list was
shown in Table S2). We used a stringent corrected false discovery
rate cut-off value to select differentially expressed genes and to
avoid false predictions arising from experimental variation in
different studies.
Identification of network hub genes for HCC classifier
To create the network, the genes (nodes) and published
literature-based connections (edges) were plotted using GeneGo-
MetaCore (Figure 2A for upregulated genes, Figure 2B for
downregulated genes and Figure 2C for both upregulated and
downregulated genes). The network architecture is consistent with
a scale-free network and represents interactions between individ-
ual targets. As the targets with high degrees of connectivity are
considered to be the most important components of a network
[20], we examined hubs with more than 30 connections and less
than 50% of edges hidden within the network. For upregulated
genes network, the 10 hubs are shown in Figure 2D: MAPK1,SP1,
HDAC1, YY1, ABL1, PTK2, SMAD2, NCOA3, CDC25A, and
NCOA2; for downregulated genes network, the 7 hubs are shown
in Figure 2E: FOS, ESR1, JUNB, EGFR, SOCS3, FOLH1, and
IGF1; for both upregulated and downregulated genes network, the
27 hubs are shown in Figure 2F: SP1, JUN, FOS, ESR1, JUNB,
Systems Biology Modeling for HCC Diagnosis
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NCOA3, SOCS3, HGF, GRB2, IGF1, NCOA2, ETS2, ATF3,
CDC25A, SERPINE1, DUSP1, ID2, MAPT and SREBF1 (the
detailed information of these hub genes is shown in Tables S3,
S4, S5).
Performance evaluation of HCC classifier
Independent validation. The independent microarray gene
expression datasets were used to test our HCC classifier.
Chen_Liver [15] (29 HCC samples and 17 non-tumor liver
tissues) and Wurmbach_Liver [16] (35 HCC samples and 27 non-
tumor liver tissues) datasets were randomly separated into the
training and test datasets, and this procedure was repeated 100
times. The weights of hub genes and score threshold in the HCC
classifier were trained by the training dataset. The predictive
accuracy and AUC value of the algorithm was then evaluated by
the test datasets, and this procedure was repeated 100 times.
Finally, the accuracy and AUC values for different tests were
summed to calculate the average and standard error.
The overall predictive accuracy and AUC values of the different
HCC classifiers, which were constructed with the 10 upregulated
hub genes (Classifier 1), 7 downregulated hub genes (Classifier 2)
and 27 differentially expressed hub genes (Classifier 3), on the
Chen_Liver and Wurmbach_Liver test datasets were shown in
Table 1, respectively. Firstly, the accuracy values of three classifiers
on different independent test datasets were 85.88(92.71% and the
AUC values were all more than 0.92(0.96. The AUC value is an
indicator of the efficacy of the assessment system. An ideal test with
perfect discrimination (100% sensitivity and 100% specificity) has
an AUC of 1.0, whereas a non-informative prediction has the area
0.5, indicating that it may be achieved by mere guess. The closer to
1.0 the AUCof a test is, the higher the overall efficacy of the test will
be [17]. We found that our HCC classifier had an area
approximating 1.0, suggesting that it had a relatively high ability
to identify the true HCC tissues against the different independent
test datasets. Secondly, Classifier 3 includes more hub genes (27)
than Classifier 1 (10) and Classifier 2 (7), but its performance (ACC
and AUC) was not significantly higher than that of the other two
classifiers. Thirdly, Classifier 2 includes the smallest number of
genes and was not significantly different from other two classifiers in
terms ofperformance,so we choseClassifier 2 forfurthervalidation.
Five-fold cross-validation. We also used the 5-fold cross-
validation protocol to evaluate the performance of our HCC
classifier (Classifier 2). The resulting ROC curves were illustrated
in Figure 3. Each point on the ROC curve denotes the sensitivity
and specificity against a set of weights and score threshold.
Because the AUC is an indicator of the discriminatory power for
the classifier, it was also used here to evaluate the predictive
efficacy of our HCC classifier. From Figure 3, we can find that our
HCC classifier had an AUC value approximating 1.0 in all the five
tests, suggesting that it has a great reliability and efficacy to identify
the true HCC tissues against different test datasets.
Validation of the contribution of the network topological
features to the classifier. In order to verify the contribution of
Figure 2. Network for upregulated genes (A), downregulated genes (B) and all differentially expressed genes (C). Hub-based network view of 10
upregulated hub genes (D), 7 downregulated hub genes (E) and 27 differentially expressed hub genes (F). GeneGO MetaCore was used to generate a
network of direct connections among genes selected for analysis. Red, green, and gray arrows indicate negative, positive, and unspecified effects,
respectively. Hubs were identified as having more than thirty connections and less than 50% of edges hidden within the network.
doi:10.1371/journal.pone.0022426.g002
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our classifier, we first added different proportions of non-hub
genes into the classifier (Classifier 2). At each ratio (7/1, 7/2, 7/4,
7/6 and 7/8) of hub and non-hub genes, the non-hub genes were
selected randomly, the process was repeated 100 times and the
average performance was shown in Figure 4A,B. From the result
we can see that the predictive accuracy and AUC values of the
classifier undergo no significant changes with the non-hub genes
added, indicating that non-hub genes contribute little to this
classifier. Then, we changed the ratio of hub and non-hub genes in
the classifier (Classifier 2). At each ratio (6/1, 5/2/3/4, 1/6 and
0/7), the hub and non-hub genes were both selected randomly, the
total number of them was maintained at 7. This process was
repeated 100 times and the average performance was shown in
Figure 4C,D. The result shows that the classifier worked much
less efficiently with the number of hub genes being gradually
reduced and the number of non-hub genes gradually increased.
Especially, the predictive accuracy and AUC values of the
classifier were decreased with statistic significance when the
proportion of hub genes was reduced to 3/7 of the original one,
indicating that the network topological features integrated into
modeling could improve the predictive performance of our
classifier.
Application of this modeling strategy to other cancers
In the above sections, we constructed HCC classifier by
combining differential gene expression and topological character-
istics of the interaction network to identify marker genes using
microarray expression data of HCC and validated that this
classifier has excellent predictive performance. We hypothesized
that this modeling strategy could be also applied to constructing
other cancers diagnosis classifiers. To test this hypothesis, we used
the same method to construct the prostate cancer diagnosis
classifier.
As the first step, two publicly available datasets of gene
expression profiles on prostate cancer were chosen, including
Liu_Prostate [21] (Normal prostate vs. prostate cancer) and
Varambally_Prostate [22] (Normal prostate vs. prostate cancer).
The detailed information about the datasets is described in Raw
Data S6, S7, S8 and Table S6. Next, in the Oncomine platform,
the genes differentially expressed in prostate cancer tissues relative
to their corresponding normal tissues were filtered by a corrected
Q value (Q#0.05) cut-off and Concept filters. 21 upregulated and
27 downregulated genes that different microarray datasets of
prostate cancer have in common were chosen as the candidate
markers for network analysis (The gene lists were shown in Table
S7). Then, their networks (Figure S1) were analyzed by GeneGO
Meta-Core software and 4 hub genes were chosen, including
BCL2, TP53, DAPK1 and CCND2 (The hub gene lists were
shown in Table S8). After that, the prostate cancer diagnostic
classifier was constructed by PLS modeling based on the
microarray gene expression data of the hub genes. Furthermore,
this classifier was tested by the independent microarray gene
expression dataset. The overall predictive accuracy was
84.7966.53% and AUC value was 0.8260.10. To verify the
contribution of the network topological features to the predictive
performance of this prostate cancer classifier, we also changed the
ratio of hub and non-hub genes in the model. As shown by the
results (Figure S2), we noticed that the predictive accuracy and
AUC values of this classifier were not significantly different from
those of the hub genes which were not being changed and non-
hub genes which were being added, but were decreased
significantly when the proportion of hub genes was reduced, as
was the case with the results of HCC classifier. (The detailed
information on the methods and results of this section were shown
in File S1.)
Biological interpretations of hub genes in HCC classifier
Cancer diagnosis classifier does not necessarily involve under-
standing the biological function and regulatory mechanism of the
gene components. However, molecular understanding of the
biological function could still be worthwhile in that the differential
expression of these genes and the interaction among them may be
mechanistically linked to carcinogenesis. We therefore surveyed
the literature and the knowledge databases such as Entrez Gene
[23], PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez?db=
pubmed), and Gene References into Function (GeneRIFs) (ftp://
ftp.ncbi.nih.gov/gene/GeneRIF/) on these hub genes. As a result,
in the 17 (10 unregulated and 7 downregulated expression in HCC
tissues) hub genes, 13 genes (SMAD2, PTK2, MAPK1, HDAC1,
CDC25A, IGFI, FOS, ESR1, EGFR, SOCS3, SP1, YY1 and
JUNB) have been identified as an HCC-related gene. Further
studies on HCC could focus on the remaining 4 genes (ABL1,
NCOA3, NCOA2 and FOLH1). In this section, we introduced the
biological features of the two most promising genes.
Table 1. Performance of HCC classifiers on different
independent test datasets.
Wurmbach_Liver test
dataset Chen_liver test dataset
Acc (%) AUC Acc (%) AUC
Classifier 1 87.2065.72 0.9260.04 85.8869.70 0.9460.05
Classifier 2 86.4465.56 0.9360.03 89.5466.52 0.9960.02
Classifier 3 88.0564.89 0.9660.02 92.7167.80 0.9660.03
doi:10.1371/journal.pone.0022426.t001
Figure 3. ROC curves for 5-fold cross-validations against the
golden standard datasets. Each point on the ROC curve denotes the
sensitivity and specificity against a set of weights and score threshold.
Different colors are used to distinguish the curves of classifier in cross-
validations for five times. AUC values are also presented in the figure.
Sensitivity and specificity are computed during the 5-fold cross-
validations (see text for details).
doi:10.1371/journal.pone.0022426.g003
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member of a proto-oncogene family of receptors important in
cell proliferation [24]. The protein encoded by this gene is a
transmembrane glycoprotein that is a member of the protein
kinase superfamily. This protein is a receptor for members of the
epidermal growth factor family. EGFR overexpression has been
demonstrated in many human carcinomas including the breast,
stomach, esophageal squamous carcinoma, and HCC [25].
Because of the high prevalence of EGFR overexpression in
carcinomas, inhibitors of epidermal growth factor (EGF) signaling
are potential therapeutic agents. In normal hepatocytes, ligand
binding to EGFR results in receptor dimerization and activation of
several possible pathways that transmit signals to the nucleus
including STAT-1, STAT-3, STAT-5, and MAPK [26]. EGFR
also signals through AKT in some cases [27]. In HCC,
overexpression of EGFR has been associated with late-stage
disease, increased cell proliferation, and the degree of tumor
differentiation [28]. Early studies of EGFR inhibitors in HCC cell
lines and phase II studies in human HCC have been encouraging.
PTK2. Protein tyrosine kinase 2 (PTK2) encodes a
cytoplasmic protein tyrosine kinase which is found concentrated
in the focal adhesions that form between cells growing in the
presence of extracellular matrix constituents [29]. The encoded
protein is a member of the focal adhesion kinase (FAK) subfamily
of protein tyrosine kinases but lacks significant sequence similarity
to kinases from other subfamilies. In HCC cell lines, the enhanced
expression of FAK changed the distributions of cytoskeleton in the
3D reconstituted basement membrane and increased the adhesion
and invasion potentials of cells [30]. It also has been demonstrated
that SOCS-3 negatively regulates cell growth and cell motility by
inhibiting Janus kinase/STAT and FAK signalings in HCC cells
[31]. In HCC tissues, FAK expression is significantly related to
subsequent metastasis [32]. Given the important role of FAK in
tumorogenesis, metastasis and survival signaling, it is regarded as a
potential target for novel anti-cancer drugs.
Validation of MAPK1 and NCOA2 hubs
We examined the hub-based model and chose to validate the
associations of MAPK1 and NCOA2 expression patterns with the
clinicopathological features of HCC, respectively.
MAPK1 was chosen because it was identified as a central hub
and had the largest number of network connections. Although it
Figure 4. Performance of HCC classifier (Classifier 2) with adding new non-hub genes (A for predictive accuracy and B for AUC
values) and with different ratios of hub and non-hub genes (C for predictive accuracy and D for AUC values). A and B showed that the
predictive performance of the classifier does not change significantly with the non-hub genes being added (p.0.05); C and D indicated that the
classifier worked much less properly with the hub genes being gradually reduced and non-hub genes gradually increased. Especially, the predictive
performance of the classifier was decreased with statistic significance when the proportion of hub genes was reduced to 3/7 of the original one
(*p,0.05).
doi:10.1371/journal.pone.0022426.g004
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is implicated in the pathogenesis of HCC, the functional role of
MAPK1 in the progression of HCC is under debate. The results of
immunohistochemical staining proved that MAPK1 expression
was absent or sporadic in PCLTs, whereas the distribution of
HCC cells with MAPK1 immunoreactivity occurred diffusely or
focally (Figure 5A and B, respectively). The MAPK1-positive cells
showed unequivocal cytoplasmic and/or nuclear staining patterns.
Of the 30 HCC tissues, 25 (83.33%) were positively expressed
MAPK1, whereas only 7 (23.33%) of 30 PCLTs were evaluated as
belonging to the MAPK1-positive group (p,0.01) (The detailed
information was shown in Table S10). Then, we compared the
clinicopathological findings of the MAPK1-positive and MAPK1-
negative groups (Table 2). The expression patterns of MAPK1 in
HCC tissues were significantly associated with the differentiation
degree (p=0.03). Tumors with positive MAPK1 expression had
lower differentiation degree than those with negative expression.
Although there was no statistic significance, the patients with
positive MAPK1 expression tended to have higher Edmondson-
Steiner grade and higher AFP level than those with negative
expression. No signicant correlations were observed with other
parameters, including age, gender, portal vein infiltration status,
TNM stage, and lymphatic metastasis status (Table 2).
NCOA2 was chosen because its correlation with HCC
progression had never been reported according to our literature
retrieval. From the results of immunohistochemical staining, we
noticed that NCOA2 expression was absent or sporadic in PCLTs,
whereas the distribution of HCC cells with NCOA2 immunore-
activity occurred diffusely or focally (Figure 5C and D,
respectively). The NCOA2-positive cells showed unequivocal
nuclear staining patterns. Of the 30 HCC tissues, 24 (80.00%)
were positively expressed NCOA2, whereas only 4 (13.33%) of 30
PCLTs were evaluated as belonging to the NCOA2-positive group
(p,0.01) (The detail information was shown in Table S11). Then,
we compared the clinicopathological findings of the NCOA2-
positive and NCOA2-negative groups (Table 3). The expression
patterns of NCOA2 in HCC tissues were significantly associated
with the Edmondson-Steiner grade (p=0.04). The positive
expression rate of NCOA2 in Edmondson-Steiner grade III,IV
group was significantly higher than that in Edmondson-Steiner
grade I,II group. Although there was no statistic significance, the
patients with positive NCOA2 expression tended to have higher
AFP level and lower differentiation degree than those with
negative expression. No signicant correlations were observed with
other parameters, including age, gender, portal vein infiltration
status, TNM stage, and lymphatic metastasis status (Table 3).
Discussion
Early and accurate diagnosis of HCC is crucial to the
development of patient tailored treatment strategies and the
improvement of patient prognosis. In this study, we developed a
novel classifier of HCC diagnosis that is based on integrating the
topological features of protein-protein interaction network with
gene expression data under disease conditions. The applicability of
this systems biology classifier of HCC diagnosis is supported by
several observations. First, we identified 10 up-regulated and 7
down-regulated hub genes that are believed to play a central role
in the progression of HCC. Among these hubs, 10 are known to
Figure 5. Immunohistochemical staining for MAPK1 and NCOA2 (Original magnification6200). A, MAPK1 expression was found in cell
cytoplasm and/or nucleus at various levels in HCC tissues; B, MAPK1 staining was negative in paracarcinomatous liver tissues; C, NCOA2 expression
was found in nucleus of tumor cells at various levels in HCC tissues; D, NCOA2 staining was negative in paracarcinomatous liver tissues.
doi:10.1371/journal.pone.0022426.g005
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others also have been identified as potential cancer related genes.
In addition, we confirmed that the expression patterns of 2 hubs–
MAPK1 and NCOA2 are significantly correlated with differen-
tiation degree and Edmondson-Steiner grade of HCC tissues,
respectively. Secondly, we developed a PLS model of HCC
classification using the hub-gene systems model. This was
independently validated by two test datasets from different
microarray platforms, their predictive accuracy was both more
than 85.00% and AUC values both approached 1.0. Thirdly, by
comparing the predictive performance of our classifier with
different ratios of hub and non-hub genes, we noticed that its
reliability and efficacy were decreased significantly with the decline
in the number of hub genes, which reflects the important
contribution of topological features of network to this classifier.
Furthermore, we confirmed that this modeling strategy is also
applicable to the diagnosis of other cancers, such as prostate
cancer.
When searching for a consensus cancer classifier, some studies
have applied a combined analysis of several microarray expression
datasets and used certain mathematical methods such as Logistic
Discrimination, Quadratic Discriminant Analysis, or analysis of
variance to ‘‘correct’’ systematic biases existing within those data
ets to train classifiers. Scherf et al. [33] used average-linkage
clustering for tumor tissues from various sites of origin. Support
Vector Machine was applied to the classification of tumor and
normal ovarian tissues by Furey et al [34]. While these methods
are certainly a step forward in the right direction, they may bring
about some problems as well. Experimental biases present in
similar datasets generated in different laboratories using different
microarray platforms can be possibly lessened or removed by those
methods. However, if datasets contain diverse patient populations,
technical and biological effects embedded in the microarray data
cannot be differentiated. Thus, the application of those methods to
‘correct’ such microarray data will remove informative biological
variability. To address this problem, some studies of gene networks
have already been used in identification of the signature of disease
mechanisms, investigation of cellular regulatory processes, hub
gene analysis, and molecular characterization of the cellular state.
Segal et al. [35] developed a module-network approach to the
identification of modules of coregulated genes by using microarray
data, enrichment analysis and promoter analysis, which is further
applied to discover the signature of the mechanisms underlying
tumorigenesis. Calvano et al. [36] integrated the structured
network knowledge-base approach, pathway analysis and micro-
array data analysis to develop an analytic method of systemic
inflammation. Liu et al. [37] developed a framework based on
cancer class-specific gene networks for classification and pathway
analysis using microarray data. Furthermore, Lu et al [10]
indicated that a major challenge to the analysis of microarray
data is the dependence of the interpretation of the biological
relevance of changes in expression on fold change or statistics. As
both approaches preferentially select genes with huge changes in
Table 2. Association of MAPK1 expression pattern with
different clinicopathologic features of HCC.
Parameters N
MAPK1 Expression
levels (n, %) p
Negative Positive
Gender
Male 22 3 (13.64) 19 (86.36) 0.30
Female 8 2 (25.00) 6 (75.00)
Age 30 56.20611.41 53.64611.40 0.42
Portal vein infiltration
Absence 28 5 (17.86) 23 (82.14) 0.69
Presence 2 0 (0) 2 (100.00)
Edmondson-Steiner
grade
I,II 20 5 (25.00) 15 (75.00) 0.11
III,IV 10 0 (0) 10 (100.00)
TNM stage
I,II 25 5 (20.00) 20 (80.00) 0.37
III,IV 5 0 (0) 5 (100.00)
AFP (ng/mL)
#400 22 5 (22.73) 17 (77.27) 0.18
.400 8 0 (0) 8 (100.00)
lymphatic metastasis
Absence 28 5 (17.86) 23 (82.14) 0.69
Presence 2 0 (0) 2 (100.00)
Differentiation degree
high 11 4 (36.36) 7 (63.64) 0.03
Moderate,low 19 1 (6.25) 18 (93.75)
doi:10.1371/journal.pone.0022426.t002
Table 3. Association of NCOA2 expression pattern with
different clinicopathologic features of HCC.
Parameters N
NCOA2 Expression
levels (n, %) p
Negative Positive
Gender
Male 22 4 (18.18) 18 (81.82) 0.34
Female 8 2 (25.00) 6 (75.00)
Age 30 55.92611.39 52.38611.26 0.45
Portal vein infiltration
Absence 28 6 (21.43) 22 (78.57) 0.63
Presence 2 0 (0) 2 (100.00)
Edmondson-Steiner
grade
I,II 20 6 (30.00) 14 (70.00) 0.04
III,IV 10 0 (0) 10 (100.00)
TNM stage
I,II 25 6 (24.00) 19 (76.00) 0.30
III,IV 5 0 (0) 5 (100.00)
AFP (ng/mL)
#400 22 6 (27.27) 16 (72.73) 0.13
.400 8 0 (0) 8 (100.00)
lymphatic metastasis
Absence 28 6 (21.43) 22 (78.57) 0.63
Presence 2 0 (0) 2 (100.00)
Differentiation degree
high 11 4 (36.36) 7 (54.55) 0.09
Moderate,low 19 2 (12.50) 17 (56.25)
doi:10.1371/journal.pone.0022426.t003
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functions would not be detected. Specifically, hub genes, which are
of high connectivity and putatively high biological importance,
may not be detected. This is why biological understanding is
enhanced by combining information including levels of change in
gene expression plus topological criteria from the analysis of
interaction networks.
In our classifier, the systematic integration of the differential
expression analysis on microarray data and topological features of
protein interaction network offers us two main advantages: First, it
enables us to sufficiently utilize the gene co-expression information
provided by the microarray data, which is believed to be more
informative than expression changes of individual genes for target
gene identification. Second, network analysis is a powerful tool to
understand pathological mechanisms of disease. By integrating the
topological features of biological network, some information lost in
the differential expression analysis is added to our classifier.
There are, however, some flaws with our classifier. First, the
analysis favored well-studied genes, because the published
literature-based primary interconnections were key criteria used
to build the network. We took this approach because hub
connectivity is correlated with the biological importance in yeast
studies [38]. Thus, the current model might not be as effective for
identifying orphan genes that function as central hubs in the
network. Second, although connectivity is the most important
topological feature for the components of biological networks, this
information is incomplete. Future studies integrating more
characteristics into our classifier should be able to provide a
keener insight into the network topology and tumorigenesis.
In conclusion, we developed a systems biology-based gene
expression classifier of HCC diagnosis by combining information
including levels of change in gene expression plus topological
features from the analysis of protein interaction networks. The
accuracy and stability of the predictive performance were
confirmed. Our modeling strategy may also prove useful for
diagnosis of other cancers.
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